Ownership and insider activity for BioAtla, Inc. (BCAB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Price
| Price | $1.74 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.9M | $3.7M | $238.6M | $245.0M | $215.5M | $111.5M | $49.0M | $7.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $12.7M | $4.5M | $240.7M | $247.3M | $220.4M | $116.4M | $51.2M | $8.0M |
| Property, Plant & Equipment | $3.9M | $4.7M | $4.1M | $7.0M | $5.2M | $3.1M | $1.2M | $5.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $16.6M | $9.3M | $244.9M | $254.4M | $225.7M | $119.7M | $52.4M | $13.8M |
| Accounts Payable | $2.0M | $5.1M | $2.5M | $1.2M | $4.2M | $3.8M | $1.9M | $8.2M |
| Short-term Debt | 0 | $9.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $9.2M | $26.7M | $32.3M | $19.8M | $23.1M | $28.3M | $14.5M | $21.9M |
| Long-term Debt | $15.0M | $8.4M | $682000 | 0 | 0 | 0 | 0 | $4.8M |
| Total Liabilities | $45.1M | $65.3M | $35.0M | $43.6M | $45.4M | $49.0M | $38.2M | $50.0M |
| Retained Earnings | -$118.6M | -$148.4M | -$90.9M | -$186.3M | -$292.8M | -$416.3M | -$486.0M | -$545.6M |
| Total Equity | -$28.5M | -$56.0M | $210.0M | $210.8M | $180.3M | $70.7M | $14.3M | -$36.2M |
| Total Debt | $15.0M | $18.1M | $682000 | $5.4M | $4.0M | $2.5M | $836000 | $6.2M |
| Net Debt | $4.1M | $14.4M | -$237.9M | -$239.6M | -$211.5M | -$109.0M | -$48.2M | -$918000 |
| Working Capital | $3.5M | -$22.2M | $208.4M | $227.5M | $197.3M | $88.1M | $36.7M | -$13.9M |
Financial Health
| Debt / Equity | -0.16 |
| Current Ratio | 0.20 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -70.06 |
Profitability
| Return on Equity | 89.25% |
| Return on Invested Capital | 318.00% |
| Return on Assets | -330.89% |
| Gross Margin | -4.15% |
| Operating Margin | -372.06% |
| Net Margin | -370.05% |
Related companies: ANVS · BTAI · CELU · EVAX · GBIO · MRSN · MURA
Explore sector: Healthcare · Biotechnology
More sections of BCAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks